盟科药业2025年净利亏损2.42亿元

Core Viewpoint - Mengke Pharmaceutical (688373) reported a revenue of 142 million yuan for the year 2025, reflecting an 8.83% year-on-year growth, while the net profit attributable to shareholders was a loss of 242 million yuan, indicating a reduction in losses [1] Group 1: Financial Performance - The company achieved an operating income of 142 million yuan in 2025, which is an increase of 8.83% compared to the previous year [1] - The net profit attributable to shareholders was a loss of 242 million yuan, showing a reduction in losses year-on-year [1] Group 2: Product and Market Strategy - During the reporting period, the company had only one product, the Contizolam Tablets, in the commercialization stage [1] - The company is actively exploring a market development model that combines self-operated teams with commercial distribution [1] Group 3: Cost Management - The company implemented measures to enhance the precision management of sales, research and development, and administrative expenses, leading to a decrease in overall costs and expenses compared to the previous year [1] - There was a reduction in idle funds used for purchasing trading financial assets, which resulted in a decline in fair value change gains [1]